08:00 , Feb 3, 2003 |  BC Week In Review  |  Company News

AlphaRx, Select Therap deal

ALRX completed its previously announced acquisition of exclusive worldwide rights to Select's VT-1, a toxin that targets CD77 on tumor cells (see BioCentury, Nov. 18, 2002). The compound is in preclinical development. AlphaRx Inc....